Two ISO-Certified Industry Leaders Collaborate
to Provide Fertility Clinics with Complete, Trusted
Solutions for Secure IVF Specimen Management and Transport
NASHVILLE, Tenn. and NEW YORK, Oct. 21,
2024 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX)
("Cryoport"), a global leader in supply chain solutions for the
life sciences industry, and TMRW Life Sciences ("TMRW"), a
fertility technology company offering the highest standard of care
in offsite storage for frozen eggs, embryos and sperm in the U.S.
with the only FDA-cleared automated specimen management and storage
platform, today announced a strategic partnership to provide
fertility clinics with complete solutions for secure specimen
management and transport.
As the demand for offsite storage of frozen specimens for
fertility clinics grows, this partnership addresses the increasing
need for reliable, efficient, and secure shipping solutions. Under
this partnership, the biologistics and transport of specimens
between the TMRW Biorepositories and fertility clinics will be
handled by Cryoport Systems, combining two industry-leading
companies committed to delivering the gold standard in fertility
specimen management and biologistics. Together, they offer
fertility clinics comprehensive, trusted solutions to manage their
growing specimen inventories with unparalleled safety and
reliability.
"This partnership with Cryoport reflects our dedication to
providing patients and clinics with the highest standard of care,"
said Louis Villalba, TMRW's CEO.
"Cryoport's reputation for excellence in reproductive biologistics,
paired with TMRW's cutting-edge specimen management technology and
safety certifications, delivers unmatched security and peace of
mind for transporting specimens in the fertility space."
Both TMRW and Cryoport are ISO-certified, underscoring their
dedication to maintaining rigorous quality standards. TMRW is the
only reproductive health storage provider with HIPAA-compliant,
military-grade data security with SOC II and HITRUST
certifications, along with cloud-based monitoring through
Overwatch® and its proprietary, cloud-based ivfOS software for
digitally managing specimens. Cryoport brings over a decade of
experience in reproductive medicine biologistics including
state-of-the-art tracking and visibility via its validated
Cryoportal® Logistics Management Platform. Together, these
certifications and advanced technologies will help to ensure that
every aspect of specimen management, storage and transport adheres
to the highest levels of safety, security and quality control.
"Cryoport is pleased to be joining forces with TMRW Life
Sciences , a leader in fertility technology, to provide clinics
with secure and seamless transport experiences for specimens,"
added Cryoport Systems President and CEO, Dr. Mark Sawicki. "Our organizations share a
mutual focus on derisking processes, innovation and quality. By
combining forces and bringing our solutions and expertise to this
endeavor, we can offer unmatched end-to-end solutions for the safe
transport, management and storage of frozen eggs, embryos and
sperm."
By leveraging TMRW's digital specimen management system and
Cryoport's expertise in temperature-controlled logistics for the
life sciences, fertility clinics, and patients can be confident in
the data integrity and safety of their specimens from clinic to
transport to storage.
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX), ),
is a global leader in supply chain solutions for the Life Sciences
with an emphasis on cell & gene therapies. Cryoport enables
manufacturers, contract manufacturers (CDMO's), contract research
organizations (CRO's), developers, and researchers to carry out
their respective business with products and services that are
designed to derisk services and provide certainty. We provide a
broad array of supply chain solutions for the life sciences
industry. Through our platform of critical products and solutions
including advanced temperature-controlled packaging, informatics,
specialized bio-logistics services, bio-storage, bio-services, and
cryogenic systems, we are "Enabling the Future of Medicine™"
worldwide, through our innovative systems, compliant procedures,
and agile approach to superior supply chain management.
Our corporate headquarters, located in Nashville, Tennessee, is complemented by over
50 global locations in 17 countries, with key sites in the United States, United Kingdom, France, the
Netherlands, Belgium,
Portugal, Germany, Japan, Australia, India, and China.
For more information, visit www.cryoportinc.com or follow via
LinkedIn at https://www.linkedin.com/company/cryoportinc or
@cryoport on X, formerly known as Twitter at www.x.com/cryoport for
live updates
About TMRW Life Sciences
Founded in 2018, TMRW Life
Sciences, Inc., is a fertility technology company digitizing the
IVF lab starting with the world's first automated platform for the
safe management and storage of frozen sperm, eggs and embryos. For
the first time, frozen specimens can be digitally identified and
tracked, safely managed with automated robotics, and remotely
monitored around the clock. TMRW's next-generation technology
platforms set a new standard of care, reducing potential points of
failure by 94% compared to manual systems. TMRW delivers peace of
mind by helping reduce the risk of specimen mix-up, damage, or
loss. Named Fast Company's #1 Most Innovative Biotech company in
2022, TMRW has been adopted by leading clinics across the United States and United Kingdom.
Forward-Looking Statements
Statements in this press
release which are not purely historical, including statements
regarding Cryoport's intentions, hopes, beliefs, expectations,
representations, projections, plans or predictions of the future,
are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, but are not limited to, those related to
Cryoport's expectations about future benefits of the partnership
with TMRW Life Sciences, including the potential impact on future
revenue and revenue streams. It is important to note that
Cryoport's actual results could differ materially from those in any
such forward-looking statements. Factors that could cause actual
results to differ materially include, but are not limited to, risks
and uncertainties associated with the effect of changing economic
and geopolitical conditions, supply chain constraints, inflationary
pressures, the effects of foreign currency fluctuations, trends in
the products markets, variations in Cryoport's cash flow, market
acceptance risks, and technical development risks. Cryoport's
business could be affected by other factors discussed in Cryoport's
SEC reports, including in the "Risk Factors" section of its most
recently filed periodic reports on Form 10-K and Form 10-Q, as well
as in its subsequent filings with the SEC. The forward-looking
statements contained in this press release speak only as of the
date hereof and Cryoport cautions investors not to place undue
reliance on these forward-looking statements. Except as required by
law, Cryoport disclaims any obligation, and does not undertake to
update or revise any forward-looking statements in this press
release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tmrw-life-sciences-and-cryoport-systems-form-strategic-partnership-to-elevate-standards-for-frozen-egg-embryo-and-sperm-offsite-storage-and-biologistics-302281490.html
SOURCE Cryoport, Inc.